Exelgyn. Topogyne, Produktresumé. Läkemedelsverket [www]. [updated 2024-06-25, cited 2025-09-16].

Pfizer. Cytotec Produktresumé. Läkemedelsverket [www]. [updated 2023-05-25, cited 2025-09-16].

Fonseca W, Alencar AJ, Pereira RM, Misago C. Congenital malformation of the scalp and cranium after failed first trimester abortion attempt with misoprostol. Clin Dysmorphol. 1993;2:76-80.

Marques-Dias MJ, Gonzalez CH, Rosemberg S. Mobius sequence in children exposed in utero to misoprostol: Neuropathological study of three cases. Birth Defects Research Part A 2003;67:1002-7.

Coelho KE, Sarmento MF, Veiga CM, Speck-Martins CE, Safatle HP, Castro CV et al. Misoprostol embryotoxicity: Clinical evaluation of fifteen patients with arthrogryposis. Am J Med Genet 2000;95:297-301.

Vargas FR, Schuler-Faccini L, Brunoni D, Kim C, Meloni VF, Sugamaya SM et al. Prenatal exposure to misoprostol and vascular disruption defects: A case-control study. Am J Med Genet 2000;95:302-6.

Orioli IM, Castilla EE. Epidemiological assessment of misoprostol teratogenicity. BJOG 2000;107:519-23.

Gonzalez CH, Marques-Dias MJ, Kim CA et al. Congenital abnormalities in Brazilian children associated with misoprostol misuse in first trimester of pregnancy. Lancet 1998;351:1624-7.

Pastuszak AL, Schuler L, Speck-Martins CE et al. Use of misoprostol during pregnancy and Mobius' syndrome in infants. N Engl J Med 1998;338:1881-5.

da Silva Dal Pizzol T, Knop FP, Mengue SS. Prenatal exposure to misoprostol and congenital anomalies: systematic review and meta-analysis. Reprod Toxicol. 2006;22:666-71.

Jingran G, Yan D, Xiaoying Y. Risk of teratogenicity in continued pregnancy after gestational exposure to mifepristone and/or misoprostol: a systematic review and meta-analysis. Arch Gynecol Obstet. 2024;310(3):1331-1342.

Danielsson B, Vargesson N, Danielsson C. Teratogenicity and Reactive Oxygen Species after transient embryonic hypoxia: Experimental and clinical evidence with focus on drugs causing failed abortion in humans. Reprod Toxicol. 2023;122:108488.

Schuler L, Pastuszak A, Sanseverino TV et al. Pregnancy outcome after exposure to misoprostol in Brazil: a prospective, controlled study. Reprod Toxicol 1999;13:147-51.

UK Teratology Information Service (UKTIS). Exposure to misoprostol in pregnancy October 2022 Version:4 . UKTIS [www]. [cited 2025-09-16].

Misoprostol and Teratogenicity: Reviewing the Evidence . Population Council may 2003 New York [www]. [cited 2025-09-17].

Sitruk-Ware R, Davey A, Sakiz E. Fetal malformation and failed medical termination of pregnancy. Lancet. 1998;352:323.

Bernard N, Elefant E, Carlier P, Tebacher M, Barjhoux CE, Bos-Thompson MA et al. Continuation of pregnancy after first-trimester exposure to mifepristone: an observational prospective study. BJOG. 2013;120(5):568-74.

UK Teratology Information Service (UKTIS). Exposure to mifepristone in pregnancy October 2022 Version: 4 . UKTIS [www]. [cited 2025-09-16].

Reprotox. Mifepristone. Micromedex [www]. Micromedex. [cited 2025-09-08].

Briggs G, Towers CV, Forinash AB. Drugs in pregnancy and lactation: A reference guide to fetal and neonatal risk. 12th ed; 2021.

Vauzelle C, Beghin D, Cournot MP, Elefant E. Birth defects after exposure to misoprostol in the first trimester of pregnancy: prospective follow-up study. Reprod Toxicol. 2013;36:98-103.

Andersen JT, Mastrogiannis D, Andersen NL, Petersen M, Broedbaek K, Cejvanovic V et al. Diclofenac/misoprostol during early pregnancy and the risk of miscarriage: a Danish nationwide cohort study. Arch Gynecol Obstet. 2016;294:245-50.

Auffret M, Bernard-Phalippon N, Dekemp J, Carlier P, Gervoise Boyer M, Vial T et al. Misoprostol exposure during the first trimester of pregnancy: Is the malformation risk varying depending on the indication?. Eur J Obstet Gynecol Reprod Biol. 2016;207:188-192.